|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TUBB3 |
Gene summary for TUBB3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TUBB3 | Gene ID | 10381 |
| Gene name | tubulin beta 3 class III | |
| Gene Alias | CDCBM | |
| Cytomap | 16q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q13509 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10381 | TUBB3 | AEH-subject1 | Human | Endometrium | AEH | 8.66e-27 | 6.25e-01 | -0.3059 |
| 10381 | TUBB3 | AEH-subject2 | Human | Endometrium | AEH | 3.50e-20 | 5.66e-01 | -0.2525 |
| 10381 | TUBB3 | AEH-subject3 | Human | Endometrium | AEH | 5.07e-14 | 4.39e-01 | -0.2576 |
| 10381 | TUBB3 | AEH-subject4 | Human | Endometrium | AEH | 2.55e-05 | 2.51e-01 | -0.2657 |
| 10381 | TUBB3 | EEC-subject1 | Human | Endometrium | EEC | 2.32e-04 | 2.42e-01 | -0.2682 |
| 10381 | TUBB3 | EEC-subject2 | Human | Endometrium | EEC | 3.29e-12 | 3.10e-01 | -0.2607 |
| 10381 | TUBB3 | EEC-subject5 | Human | Endometrium | EEC | 2.28e-02 | 1.97e-01 | -0.249 |
| 10381 | TUBB3 | LZE4T | Human | Esophagus | ESCC | 3.08e-23 | 9.24e-01 | 0.0811 |
| 10381 | TUBB3 | LZE7T | Human | Esophagus | ESCC | 1.18e-25 | 2.04e+00 | 0.0667 |
| 10381 | TUBB3 | LZE8T | Human | Esophagus | ESCC | 2.36e-06 | 2.55e-01 | 0.067 |
| 10381 | TUBB3 | LZE20T | Human | Esophagus | ESCC | 1.59e-12 | 5.17e-01 | 0.0662 |
| 10381 | TUBB3 | LZE22T | Human | Esophagus | ESCC | 8.47e-11 | 9.48e-01 | 0.068 |
| 10381 | TUBB3 | LZE24T | Human | Esophagus | ESCC | 7.65e-05 | 2.52e-01 | 0.0596 |
| 10381 | TUBB3 | LZE21T | Human | Esophagus | ESCC | 8.02e-04 | 6.75e-01 | 0.0655 |
| 10381 | TUBB3 | LZE6T | Human | Esophagus | ESCC | 1.71e-05 | 2.51e-01 | 0.0845 |
| 10381 | TUBB3 | P1T-E | Human | Esophagus | ESCC | 1.23e-18 | 9.10e-01 | 0.0875 |
| 10381 | TUBB3 | P2T-E | Human | Esophagus | ESCC | 7.90e-03 | 1.08e-01 | 0.1177 |
| 10381 | TUBB3 | P4T-E | Human | Esophagus | ESCC | 2.93e-53 | 1.54e+00 | 0.1323 |
| 10381 | TUBB3 | P5T-E | Human | Esophagus | ESCC | 1.03e-89 | 1.83e+00 | 0.1327 |
| 10381 | TUBB3 | P8T-E | Human | Esophagus | ESCC | 7.98e-13 | 3.40e-01 | 0.0889 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00074098 | Endometrium | AEH | axonogenesis | 81/2100 | 418/18723 | 5.54e-07 | 2.12e-05 | 81 |
| GO:00615648 | Endometrium | AEH | axon development | 88/2100 | 467/18723 | 6.39e-07 | 2.38e-05 | 88 |
| GO:006156412 | Endometrium | EEC | axon development | 93/2168 | 467/18723 | 9.60e-08 | 4.69e-06 | 93 |
| GO:000740912 | Endometrium | EEC | axonogenesis | 82/2168 | 418/18723 | 1.03e-06 | 3.49e-05 | 82 |
| GO:006156415 | Esophagus | ESCC | axon development | 251/8552 | 467/18723 | 2.41e-04 | 1.49e-03 | 251 |
| GO:000740915 | Esophagus | ESCC | axonogenesis | 219/8552 | 418/18723 | 3.14e-03 | 1.31e-02 | 219 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501226 | Endometrium | AEH | Parkinson disease | 115/1197 | 266/8465 | 6.24e-32 | 1.01e-29 | 7.42e-30 | 115 |
| hsa0502020 | Endometrium | AEH | Prion disease | 110/1197 | 273/8465 | 2.39e-27 | 2.44e-25 | 1.78e-25 | 110 |
| hsa0501620 | Endometrium | AEH | Huntington disease | 118/1197 | 306/8465 | 3.00e-27 | 2.44e-25 | 1.78e-25 | 118 |
| hsa0501420 | Endometrium | AEH | Amyotrophic lateral sclerosis | 123/1197 | 364/8465 | 2.17e-22 | 7.82e-21 | 5.72e-21 | 123 |
| hsa0501020 | Endometrium | AEH | Alzheimer disease | 124/1197 | 384/8465 | 1.20e-20 | 3.91e-19 | 2.86e-19 | 124 |
| hsa0502220 | Endometrium | AEH | Pathways of neurodegeneration - multiple diseases | 137/1197 | 476/8465 | 9.27e-18 | 2.32e-16 | 1.70e-16 | 137 |
| hsa0513226 | Endometrium | AEH | Salmonella infection | 71/1197 | 249/8465 | 1.69e-09 | 3.44e-08 | 2.52e-08 | 71 |
| hsa0513026 | Endometrium | AEH | Pathogenic Escherichia coli infection | 50/1197 | 197/8465 | 1.72e-05 | 1.86e-04 | 1.36e-04 | 50 |
| hsa0414524 | Endometrium | AEH | Phagosome | 41/1197 | 152/8465 | 2.12e-05 | 2.22e-04 | 1.63e-04 | 41 |
| hsa048144 | Endometrium | AEH | Motor proteins | 42/1197 | 193/8465 | 2.41e-03 | 1.42e-02 | 1.04e-02 | 42 |
| hsa05012111 | Endometrium | AEH | Parkinson disease | 115/1197 | 266/8465 | 6.24e-32 | 1.01e-29 | 7.42e-30 | 115 |
| hsa05020110 | Endometrium | AEH | Prion disease | 110/1197 | 273/8465 | 2.39e-27 | 2.44e-25 | 1.78e-25 | 110 |
| hsa05016110 | Endometrium | AEH | Huntington disease | 118/1197 | 306/8465 | 3.00e-27 | 2.44e-25 | 1.78e-25 | 118 |
| hsa05014110 | Endometrium | AEH | Amyotrophic lateral sclerosis | 123/1197 | 364/8465 | 2.17e-22 | 7.82e-21 | 5.72e-21 | 123 |
| hsa05010110 | Endometrium | AEH | Alzheimer disease | 124/1197 | 384/8465 | 1.20e-20 | 3.91e-19 | 2.86e-19 | 124 |
| hsa05022110 | Endometrium | AEH | Pathways of neurodegeneration - multiple diseases | 137/1197 | 476/8465 | 9.27e-18 | 2.32e-16 | 1.70e-16 | 137 |
| hsa05132112 | Endometrium | AEH | Salmonella infection | 71/1197 | 249/8465 | 1.69e-09 | 3.44e-08 | 2.52e-08 | 71 |
| hsa05130112 | Endometrium | AEH | Pathogenic Escherichia coli infection | 50/1197 | 197/8465 | 1.72e-05 | 1.86e-04 | 1.36e-04 | 50 |
| hsa04145111 | Endometrium | AEH | Phagosome | 41/1197 | 152/8465 | 2.12e-05 | 2.22e-04 | 1.63e-04 | 41 |
| hsa0481411 | Endometrium | AEH | Motor proteins | 42/1197 | 193/8465 | 2.41e-03 | 1.42e-02 | 1.04e-02 | 42 |
| Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TUBB3 | SNV | Missense_Mutation | rs751967547 | c.721N>T | p.Arg241Cys | p.R241C | Q13509 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.996) | TCGA-A2-A3XS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
| TUBB3 | SNV | Missense_Mutation | c.973G>C | p.Glu325Gln | p.E325Q | Q13509 | protein_coding | deleterious_low_confidence(0.01) | benign(0.429) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TUBB3 | SNV | Missense_Mutation | c.984G>T | p.Glu328Asp | p.E328D | Q13509 | protein_coding | tolerated_low_confidence(0.26) | benign(0.006) | TCGA-EW-A1P7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | PD | |
| TUBB3 | SNV | Missense_Mutation | novel | c.940G>A | p.Ala314Thr | p.A314T | Q13509 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.899) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TUBB3 | SNV | Missense_Mutation | c.302G>T | p.Trp101Leu | p.W101L | Q13509 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.986) | TCGA-AA-3818-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TUBB3 | SNV | Missense_Mutation | rs770484819 | c.557C>T | p.Thr186Met | p.T186M | Q13509 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.999) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| TUBB3 | SNV | Missense_Mutation | c.362G>A | p.Arg121Gln | p.R121Q | Q13509 | protein_coding | deleterious_low_confidence(0.05) | probably_damaging(0.944) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TUBB3 | SNV | Missense_Mutation | rs587784504 | c.1331N>T | p.Ser444Leu | p.S444L | Q13509 | protein_coding | tolerated_low_confidence(0.25) | benign(0.32) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD |
| TUBB3 | SNV | Missense_Mutation | c.484N>T | p.Arg162Cys | p.R162C | Q13509 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.997) | TCGA-QG-A5Z2-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TUBB3 | SNV | Missense_Mutation | c.1293N>T | p.Glu431Asp | p.E431D | Q13509 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-AG-A026-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 10381 | TUBB3 | DRUGGABLE GENOME | PODOFILOX | PODOFILOX | 17765552,24953821,21402478 | |
| 10381 | TUBB3 | DRUGGABLE GENOME | CHEMBL2304041 | SAGOPILONE | ||
| 10381 | TUBB3 | DRUGGABLE GENOME | PACLITAXEL | PACLITAXEL | 23631389,25369367,25768699,24457094,22595423,23313639,17887662,23387901,19758808,23725535,24953821 | |
| 10381 | TUBB3 | DRUGGABLE GENOME | NSC-751382 | CHEMBL1935538 | 22435708 | |
| 10381 | TUBB3 | DRUGGABLE GENOME | VORINOSTAT | VORINOSTAT | 20491440 | |
| 10381 | TUBB3 | DRUGGABLE GENOME | inhibitor | CHEMBL1742994 | BRENTUXIMAB VEDOTIN | |
| 10381 | TUBB3 | DRUGGABLE GENOME | inhibitor | CHEMBL1683544 | ERIBULIN MESYLATE | |
| 10381 | TUBB3 | DRUGGABLE GENOME | 10,11-DIHYDROEPOTHILONE D | CHEMBL453818 | 12141877 | |
| 10381 | TUBB3 | DRUGGABLE GENOME | IXABEPILONE | IXABEPILONE | ||
| 10381 | TUBB3 | DRUGGABLE GENOME | MAYTANSINE | MAYTANSINE | 563462 |
| Page: 1 2 3 4 5 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |